Peanut Allergy Vaccine R&D Increases with Significant Investment to Better Understand Immune Signatures Critical to Modulating Immune Responses to Allergens

 

In the U.S., peanut allergy is present in 0.6% of the population. Among children in the Western world, rates are between 1.5% and 3% and have increased over time. This has led to increasing investment in Peanut Allergy Vaccine. In December 2020, researchers at University of South Australia and Sementis received an NHMRC Ideas Grant that will support the team to better understand the immune signatures critical to modulating immune responses to allergens.

It seems that when looking for treatments, there are two that constantly come up: Peanut Allergy Vaccine and Vaximab. Both of these are FDA approved but there are many people who question the efficiency of using human samples in treating diseases. Human samples cannot work at full capacity due to the various levels of gluten they may contain. It is also important to note that Vaximab clinical trial has not yet begun.

The main argument against the use of Peanut Allergy Vaccine is that it lacks a proof of efficacy. However, researchers are still working on the formula, but progress is being made. If more success is to be had, then clinical trials will definitely be conducted. Also, there is a lack of data on the prevalence of Vaximab among people who actually have food allergies. However, the prevalence of peanut allergy vaccines in countries like Canada and the US is actually low. So even if it is unable to give a concrete cure, it has already provided relief to millions of peanut allergic patients.

Peanut immunotherapy has been around for years, and it was used to treat peanut allergies in the past. However, it was not until recent years that this method was further developed and improved. The improvement is based on the fact that peanut allergy vaccine is able to prevent anaphylactic reactions to the allergen while being able to prevent other serious complications as well. It is also able to provide long term protection from peanut allergy anaphylaxis. But as with any medication, peanut allergy immunotherapy also has its own side effects, which needs to be monitored and managed.